Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction

15 May 2019

Abstract excerpt

PURPOSE: BRCA1 and BRCA2 deficiencies are widespread drivers of human cancers that await the development of targeted therapies. We aimed to identify novel synthetic lethal relationships with therapeutic potential using BRCA-deficient isogenic backgrounds. EXPERIMENTAL DESIGN: We developed a phenotypic screening technology to simultaneously search for synthetic lethal (SL) interactions in BRCA1- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Microtubule and mitosis dynamics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30890549
DOI: 10.1158/1078-0432.ccr-18-3516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality InductionPMID 30890549Read ↗

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read ↗

The CINs of Polo-Like Kinase 1 in CancerSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read ↗

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibitionSemantic proximity Read ↗

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamicsSemantic proximity Read ↗

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsSemantic proximity Read ↗

Therapeutic relevance of the protein phosphatase 2A in cancer.Semantic proximity Read ↗

Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical GeneticsSemantic proximity Read ↗

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapySemantic proximity Read ↗

Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in miceSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.